Expired
Lead Plaintiff Deadline
Mar 20, 2023
Choose your preferred way to stay informed of new case launches and settlement deadlines
The filed complaint alleges that Y-mAbs Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that:
(i) Y-mAbs misrepresented the U.S. Food and Drug Administration’s (“FDA”) willingness to approve omburtamab, the Company's lead product candidate, for marketing based on the existing clinical trials; (ii) the Company misrepresented that progress was being made that would align with the FDA’s requirements to demonstrate substantial evidence of effectiveness, sufficient for approval of omburtamab, through adequate and well-controlled studies; (iii) the FDA had repeatedly advised Y-mAbs that it was unlikely to grant approval for the marketing of omburtamab; and (iv) Y-mAbs had elected to submit the March 31, 2022 Biologics License Application prior to reaching agreement with the FDA on the content of the application.
In order to be eligible to join the YMAB class action lawsuit, you must have incurred a loss on shares of Y-mAbs purchased during the class period listed above.
If you suffered a loss in Y-mAbs during the relevant time frame, you have until March 20, 2023 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
TOP
